Iambic takes the lead for Next-Gen AI Drug Discovery with Lambda

Iambic Named to CNBC’s 2025 Disruptor 50 List

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins

Iambic to Participate in June Investor Conferences

Panel presentation at the Bank of America Healthcare Conference

Iambic Announces Enchant v2, its Next Generation AI Model for Predicting the Clinical Viability of Drug Discovery Programs

Enchant v2: Pushing the Boundaries of Predictive Drug Discovery

A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)

Poster presented at the 2025 American Association of Cancer Research Annual Meeting